Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)

Masahiro Fukuoka, Yi Long Wu, Sumitra Thongprasert, Patrapim Sunpaweravong, Swan Swan Leong, Virote Sriuranpong, Tsu Yi Chao, Kazuhiko Nakagawa, Da Tong Chu, Nagahiro Saijo, Emma L. Duffield, Yuri Rukazenkov, Georgina Speake, Haiyi Jiang, Alison A. Armour, Ka Fai To, James Chih Hsin Yang, Tony S K Mok

Research output: Contribution to journalArticle

915 Citations (Scopus)

Abstract

Purpose: The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with advanced pulmonary adenocarcinoma were published previously. This report presents overall survival (OS) and efficacy according to epidermal growth factor receptor (EGFR) biomarker status. Patients and Methods: In all, 1,217 patients were randomly assigned. Biomarkers analyzed were EGFR mutation (amplification mutation refractory system; 437 patients evaluable), EGFR gene copy number (fluorescent in situ hybridization; 406 patients evaluable), and EGFR protein expression (immunohistochemistry; 365 patients evaluable). OS analysis was performed at 78% maturity. A Cox proportional hazards model was used to assess biomarker status by randomly assigned treatment interactions for progression-free survival (PFS) and OS. Results: OS (954 deaths) was similar for gefitinib and carboplatin/paclitaxel with no significant difference between treatments overall (hazard ratio [HR], 0.90; 95% CI, 0.79 to 1.02; P = .109) or in EGFR mutation - positive (HR, 1.00; 95% CI, 0.76 to 1.33; P = .990) or EGFR mutation - negative (HR, 1.18; 95% CI, 0.86 to 1.63; P = .309; treatment by EGFR mutation interaction P = .480) subgroups. A high proportion (64.3%) of EGFR mutation - positive patients randomly assigned to carboplatin/paclitaxel received subsequent EGFR tyrosine kinase inhibitors. PFS was significantly longer with gefitinib for patients whose tumors had both high EGFR gene copy number and EGFR mutation (HR, 0.48; 95% CI, 0.34 to 0.67) but significantly shorter when high EGFR gene copy number was not accompanied by EGFR mutation (HR, 3.85; 95% CI, 2.09 to 7.09). Conclusion: EGFR mutations are the strongest predictive biomarker for PFS and tumor response to first-line gefitinib versus carboplatin/paclitaxel. The predictive value of EGFR gene copy number was driven by coexisting EGFR mutation (post hoc analysis). Treatment-related differences observed for PFS in the EGFR mutation - positive subgroup were not apparent for OS. OS results were likely confounded by the high proportion of patients crossing over to the alternative treatment.

Original languageEnglish
Pages (from-to)2866-2874
Number of pages9
JournalJournal of Clinical Oncology
Volume29
Issue number21
DOIs
Publication statusPublished - Jul 20 2011
Externally publishedYes

Fingerprint

Carboplatin
Paclitaxel
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Biomarkers
Survival
Mutation
erbB-1 Genes
Gene Dosage
Disease-Free Survival
gefitinib
Therapeutics
Survival Analysis
Fluorescence In Situ Hybridization
Proportional Hazards Models
Protein-Tyrosine Kinases
Neoplasms
Immunohistochemistry

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS). / Fukuoka, Masahiro; Wu, Yi Long; Thongprasert, Sumitra; Sunpaweravong, Patrapim; Leong, Swan Swan; Sriuranpong, Virote; Chao, Tsu Yi; Nakagawa, Kazuhiko; Chu, Da Tong; Saijo, Nagahiro; Duffield, Emma L.; Rukazenkov, Yuri; Speake, Georgina; Jiang, Haiyi; Armour, Alison A.; To, Ka Fai; Yang, James Chih Hsin; Mok, Tony S K.

In: Journal of Clinical Oncology, Vol. 29, No. 21, 20.07.2011, p. 2866-2874.

Research output: Contribution to journalArticle

Fukuoka, M, Wu, YL, Thongprasert, S, Sunpaweravong, P, Leong, SS, Sriuranpong, V, Chao, TY, Nakagawa, K, Chu, DT, Saijo, N, Duffield, EL, Rukazenkov, Y, Speake, G, Jiang, H, Armour, AA, To, KF, Yang, JCH & Mok, TSK 2011, 'Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)', Journal of Clinical Oncology, vol. 29, no. 21, pp. 2866-2874. https://doi.org/10.1200/JCO.2010.33.4235
Fukuoka, Masahiro ; Wu, Yi Long ; Thongprasert, Sumitra ; Sunpaweravong, Patrapim ; Leong, Swan Swan ; Sriuranpong, Virote ; Chao, Tsu Yi ; Nakagawa, Kazuhiko ; Chu, Da Tong ; Saijo, Nagahiro ; Duffield, Emma L. ; Rukazenkov, Yuri ; Speake, Georgina ; Jiang, Haiyi ; Armour, Alison A. ; To, Ka Fai ; Yang, James Chih Hsin ; Mok, Tony S K. / Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS). In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 21. pp. 2866-2874.
@article{5374181a03a444a196514c7f5a494345,
title = "Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)",
abstract = "Purpose: The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with advanced pulmonary adenocarcinoma were published previously. This report presents overall survival (OS) and efficacy according to epidermal growth factor receptor (EGFR) biomarker status. Patients and Methods: In all, 1,217 patients were randomly assigned. Biomarkers analyzed were EGFR mutation (amplification mutation refractory system; 437 patients evaluable), EGFR gene copy number (fluorescent in situ hybridization; 406 patients evaluable), and EGFR protein expression (immunohistochemistry; 365 patients evaluable). OS analysis was performed at 78{\%} maturity. A Cox proportional hazards model was used to assess biomarker status by randomly assigned treatment interactions for progression-free survival (PFS) and OS. Results: OS (954 deaths) was similar for gefitinib and carboplatin/paclitaxel with no significant difference between treatments overall (hazard ratio [HR], 0.90; 95{\%} CI, 0.79 to 1.02; P = .109) or in EGFR mutation - positive (HR, 1.00; 95{\%} CI, 0.76 to 1.33; P = .990) or EGFR mutation - negative (HR, 1.18; 95{\%} CI, 0.86 to 1.63; P = .309; treatment by EGFR mutation interaction P = .480) subgroups. A high proportion (64.3{\%}) of EGFR mutation - positive patients randomly assigned to carboplatin/paclitaxel received subsequent EGFR tyrosine kinase inhibitors. PFS was significantly longer with gefitinib for patients whose tumors had both high EGFR gene copy number and EGFR mutation (HR, 0.48; 95{\%} CI, 0.34 to 0.67) but significantly shorter when high EGFR gene copy number was not accompanied by EGFR mutation (HR, 3.85; 95{\%} CI, 2.09 to 7.09). Conclusion: EGFR mutations are the strongest predictive biomarker for PFS and tumor response to first-line gefitinib versus carboplatin/paclitaxel. The predictive value of EGFR gene copy number was driven by coexisting EGFR mutation (post hoc analysis). Treatment-related differences observed for PFS in the EGFR mutation - positive subgroup were not apparent for OS. OS results were likely confounded by the high proportion of patients crossing over to the alternative treatment.",
author = "Masahiro Fukuoka and Wu, {Yi Long} and Sumitra Thongprasert and Patrapim Sunpaweravong and Leong, {Swan Swan} and Virote Sriuranpong and Chao, {Tsu Yi} and Kazuhiko Nakagawa and Chu, {Da Tong} and Nagahiro Saijo and Duffield, {Emma L.} and Yuri Rukazenkov and Georgina Speake and Haiyi Jiang and Armour, {Alison A.} and To, {Ka Fai} and Yang, {James Chih Hsin} and Mok, {Tony S K}",
year = "2011",
month = "7",
day = "20",
doi = "10.1200/JCO.2010.33.4235",
language = "English",
volume = "29",
pages = "2866--2874",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "21",

}

TY - JOUR

T1 - Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)

AU - Fukuoka, Masahiro

AU - Wu, Yi Long

AU - Thongprasert, Sumitra

AU - Sunpaweravong, Patrapim

AU - Leong, Swan Swan

AU - Sriuranpong, Virote

AU - Chao, Tsu Yi

AU - Nakagawa, Kazuhiko

AU - Chu, Da Tong

AU - Saijo, Nagahiro

AU - Duffield, Emma L.

AU - Rukazenkov, Yuri

AU - Speake, Georgina

AU - Jiang, Haiyi

AU - Armour, Alison A.

AU - To, Ka Fai

AU - Yang, James Chih Hsin

AU - Mok, Tony S K

PY - 2011/7/20

Y1 - 2011/7/20

N2 - Purpose: The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with advanced pulmonary adenocarcinoma were published previously. This report presents overall survival (OS) and efficacy according to epidermal growth factor receptor (EGFR) biomarker status. Patients and Methods: In all, 1,217 patients were randomly assigned. Biomarkers analyzed were EGFR mutation (amplification mutation refractory system; 437 patients evaluable), EGFR gene copy number (fluorescent in situ hybridization; 406 patients evaluable), and EGFR protein expression (immunohistochemistry; 365 patients evaluable). OS analysis was performed at 78% maturity. A Cox proportional hazards model was used to assess biomarker status by randomly assigned treatment interactions for progression-free survival (PFS) and OS. Results: OS (954 deaths) was similar for gefitinib and carboplatin/paclitaxel with no significant difference between treatments overall (hazard ratio [HR], 0.90; 95% CI, 0.79 to 1.02; P = .109) or in EGFR mutation - positive (HR, 1.00; 95% CI, 0.76 to 1.33; P = .990) or EGFR mutation - negative (HR, 1.18; 95% CI, 0.86 to 1.63; P = .309; treatment by EGFR mutation interaction P = .480) subgroups. A high proportion (64.3%) of EGFR mutation - positive patients randomly assigned to carboplatin/paclitaxel received subsequent EGFR tyrosine kinase inhibitors. PFS was significantly longer with gefitinib for patients whose tumors had both high EGFR gene copy number and EGFR mutation (HR, 0.48; 95% CI, 0.34 to 0.67) but significantly shorter when high EGFR gene copy number was not accompanied by EGFR mutation (HR, 3.85; 95% CI, 2.09 to 7.09). Conclusion: EGFR mutations are the strongest predictive biomarker for PFS and tumor response to first-line gefitinib versus carboplatin/paclitaxel. The predictive value of EGFR gene copy number was driven by coexisting EGFR mutation (post hoc analysis). Treatment-related differences observed for PFS in the EGFR mutation - positive subgroup were not apparent for OS. OS results were likely confounded by the high proportion of patients crossing over to the alternative treatment.

AB - Purpose: The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with advanced pulmonary adenocarcinoma were published previously. This report presents overall survival (OS) and efficacy according to epidermal growth factor receptor (EGFR) biomarker status. Patients and Methods: In all, 1,217 patients were randomly assigned. Biomarkers analyzed were EGFR mutation (amplification mutation refractory system; 437 patients evaluable), EGFR gene copy number (fluorescent in situ hybridization; 406 patients evaluable), and EGFR protein expression (immunohistochemistry; 365 patients evaluable). OS analysis was performed at 78% maturity. A Cox proportional hazards model was used to assess biomarker status by randomly assigned treatment interactions for progression-free survival (PFS) and OS. Results: OS (954 deaths) was similar for gefitinib and carboplatin/paclitaxel with no significant difference between treatments overall (hazard ratio [HR], 0.90; 95% CI, 0.79 to 1.02; P = .109) or in EGFR mutation - positive (HR, 1.00; 95% CI, 0.76 to 1.33; P = .990) or EGFR mutation - negative (HR, 1.18; 95% CI, 0.86 to 1.63; P = .309; treatment by EGFR mutation interaction P = .480) subgroups. A high proportion (64.3%) of EGFR mutation - positive patients randomly assigned to carboplatin/paclitaxel received subsequent EGFR tyrosine kinase inhibitors. PFS was significantly longer with gefitinib for patients whose tumors had both high EGFR gene copy number and EGFR mutation (HR, 0.48; 95% CI, 0.34 to 0.67) but significantly shorter when high EGFR gene copy number was not accompanied by EGFR mutation (HR, 3.85; 95% CI, 2.09 to 7.09). Conclusion: EGFR mutations are the strongest predictive biomarker for PFS and tumor response to first-line gefitinib versus carboplatin/paclitaxel. The predictive value of EGFR gene copy number was driven by coexisting EGFR mutation (post hoc analysis). Treatment-related differences observed for PFS in the EGFR mutation - positive subgroup were not apparent for OS. OS results were likely confounded by the high proportion of patients crossing over to the alternative treatment.

UR - http://www.scopus.com/inward/record.url?scp=79960702788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960702788&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.33.4235

DO - 10.1200/JCO.2010.33.4235

M3 - Article

C2 - 21670455

AN - SCOPUS:79960702788

VL - 29

SP - 2866

EP - 2874

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 21

ER -